Mar 01, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication
Feb 27, 2019
Overall Use of Sanofi/Regeneron's Dupixent for the Treatment of Atopic Dermatitis in the EU5 Lags that of the US, Though Side Effects and Short-Term Use in Both Markets May be Cause for Concern
Feb 25, 2019
Positive Results Presented from Two Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Feb 25, 2019
Jury Upholds Amgen's Patents On Repatha® (evolocumab)
Feb 11, 2019
Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Feb 07, 2019
Sanofi delivers 2018 business EPS growth of 5.1% at CER
Feb 06, 2019
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
Feb 04, 2019
CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Jan 24, 2019
Cutaneous Squamous Cell Carcinoma (cSCC) Market Insights, Epidemiology and Market Forecasts, 2016-2018 & 2027
Jan 23, 2019
Forty of the Nation's Most Brilliant Young Scientists Named Finalists in Regeneron Science Talent Search 2019
Jan 18, 2019
Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019
Jan 07, 2019
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Jan 07, 2019
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Jan 03, 2019
Regeneron Science Talent Search to Announce 300 U.S. High School Scholars
Dec 21, 2018
FDA approves first treatment for rare blood disease
Dec 01, 2018
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Nov 20, 2018
Regeneron Announces Upcoming Investor Conference Presentation
Nov 11, 2018
ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
Nov 07, 2018
Sanofi/Regeneron's Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment
Nov 06, 2018
Regeneron Reports Third Quarter 2018 Financial and Operating Results